论文部分内容阅读
组织因子(TF)是凝血途径的启动因子,与动脉粥样硬化的病理生理过程及临床并发症密切相关。凝血和炎症共同作用导致动脉粥样硬化,二者也是心肌无复流的发生发展基础,TF将凝血和炎症紧密联系,使二者相互作用。近些年发现心肌缺血再灌注损伤的动物模型中,缺血心肌TF表达增高,应用抑制TF的单抗可使心肌梗死面积减少,实验动物输注TF可促进心肌无复流的发生。急性冠状动脉无复流的患者TF水平也升高。TF可作为心肌无复流的预测指标。组织因子途径抑制物(TFPI)是TF的生理抑制剂,动物实验表明TFPI有抗血栓、抗炎症、抗增殖作用,输注TFPI可减轻心肌无复流的程度,为治疗心肌无复流开辟了新领域。
Tissue factor (TF) is the initiating factor of coagulation pathway, which is closely related to the pathophysiological process and clinical complications of atherosclerosis. Coagulation and inflammation together lead to atherosclerosis, both of which are the basis for the occurrence and development of myocardial no-reflow, TF will coagulation and inflammation are closely linked so that the two interact. In recent years, myocardial ischemia-reperfusion injury was found in animal models of ischemic myocardial TF increased, the application of anti-TF monoclonal antibody can reduce the area of myocardial infarction, experimental animals infused TF can promote the occurrence of myocardial no-reflow. Patients with acute coronary artery no-reflow also have elevated TF levels. TF can be used as a predictive marker of myocardial no-reflow. TFPI is a physiological inhibitor of TF. Animal experiments show that TFPI has antithrombotic, anti-inflammatory and antiproliferative effects. Infusion of TFPI can reduce the degree of myocardial no-reflow and open up the treatment of myocardial no-reflow New Field.